Straits Times Index
3,090.31 +17.32 (+0.56%) Nikkei
33,431.51 -55.38 (-0.17%) Hang Seng
16,830.30 -212.58 (-1.25%) FTSE 100
7,529.35 +75.60 (+1.01%) Bitcoin USD
39,488.01 +727.06 (+1.88%) CMC Crypto 200
802.76 +11.20 (+1.41%)
Novo Nordisk A/S (0TDD.L)
| Previous close | 101.49 |
| Open | 100.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 100.00 - 101.72 |
| 52-week range | 62.74 - 105.68 |
| Volume | |
| Avg. volume | 18,200 |
| Market cap | 2.294B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 0.33 |
| EPS (TTM) | 3.03 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Motley Fool3 No-Brainer Growth Stocks to Buy in December
Three Motley Fool contributors believe they've identified such exceptions. Here's why they think Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer growth stocks to buy in December. David Jagielski (Eli Lilly): Eli Lilly is becoming a beast in the healthcare industry.
Motley FoolEveryone Is Talking About This Stock. Is It a Good Long-Term Option?
Artificial intelligence has undoubtedly been the hottest investing topic on Wall Street this year. Led by such products as Wegovy, manufactured by Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), the area of obesity care is garnering substantial attention. One of Novo Nordisk's strengths is its focus on diabetes and obesity care.
Motley FoolIs Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.
